6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
6-K：Tolebrutinib被FDA指定為治療非復發性繼發性進展型多發性硬化癥的突破性療法，以及Duvakitug 2b期陽性結果表明其在潰瘍性結腸炎和克羅恩病領域具有同類最佳的潛力
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間